Sensyne Health | Life Sciences
Our current SRA and data sharing partnerships include:
What is your definition of ‘anonymised data’?
What is the process for accessing and anonymising patient data?
Who controls the patient data?
How does a health system transfer anonymised patient data to Sensyne Health?
What are Sensyne Health’s cyber security protections for the anonymised patient data?
Will the health system’s patient data be shared with pharmaceutical clients?
Does Sensyne Health ever sell anonymised patient data to any third party?
What are the patient benefits that can arise from the research that is undertaken by the partnership?
How can we be confident that our data is being used ethically and analysed in a secure environment?
What happens to the patient data once you have analysed it?
What are the research questions that Sensyne is currently working on with other health systems i.e. What clinical areas are you focused on?
How does a partner health system receive a royalty share?
How can health systems contribute to the development of the partnership with Sensyne Health?
What is Sensyne Health’s position on exclusivity?
How does this align with the NHS England guidance on exclusivity?
What types of data are required, is there a minimum number of records required?
Our health system is also a customer of your Healthcare products division, how do you handle this data?
How will you interact with a health system as part of an SRA? What processes do you have in place?
Can the partnership be leveraged to improve the care for patients?
How does Sensyne Health support the health system develop it research capability?
Does Sensyne Health abide by the principles set out in the DHSC’s Guidance document: ‘Creating the right framework to realise the benefits for patients and the NHS where data underpins innovation’?